Brokers Set Expectations for ESPR FY2027 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities researchers at Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued on Tuesday, March 25th. Zacks Research analyst K. Das forecasts that the biopharmaceutical company will post earnings per share of $0.06 for the year. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share.

A number of other analysts also recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday, December 13th. The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research note on Thursday, March 20th. Cantor Fitzgerald assumed coverage on Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price objective for the company. Finally, JMP Securities reissued a “market outperform” rating and set a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Esperion Therapeutics presently has an average rating of “Hold” and an average price target of $6.75.

Esperion Therapeutics Stock Down 6.8 %

ESPR opened at $1.50 on Thursday. Esperion Therapeutics has a 52 week low of $1.47 and a 52 week high of $3.94. The firm has a 50-day simple moving average of $1.78 and a two-hundred day simple moving average of $2.07. The company has a market capitalization of $296.77 million, a PE ratio of -2.34 and a beta of 1.04.

Institutional Investors Weigh In On Esperion Therapeutics

Hedge funds have recently modified their holdings of the business. Wasatch Advisors LP lifted its holdings in Esperion Therapeutics by 38.4% during the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after buying an additional 6,483,070 shares during the period. Nuveen Asset Management LLC raised its position in shares of Esperion Therapeutics by 48.6% in the 4th quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company’s stock worth $6,862,000 after acquiring an additional 1,020,243 shares in the last quarter. Bank of America Corp DE boosted its position in Esperion Therapeutics by 45.1% during the fourth quarter. Bank of America Corp DE now owns 1,629,980 shares of the biopharmaceutical company’s stock valued at $3,586,000 after purchasing an additional 506,428 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Esperion Therapeutics by 18.6% during the fourth quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company’s stock valued at $5,399,000 after purchasing an additional 385,099 shares in the last quarter. Finally, Public Employees Retirement System of Ohio bought a new position in Esperion Therapeutics in the third quarter worth about $606,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.